Central desire — melanocortin & dopaminergic

What actually decides this outcome, in order of size

Desire is generated centrally and is measured differently from function. What decides it, in order:

1. Which system is actually failing, because the two were measured with different end points. Wanting and being able are separate systems with separate receptors, and the separation is the reason this pathway exists. A PDE5 inhibitor produced successful intercourse attempts in a majority of men in its registration trials Goldstein 1998 and does nothing whatsoever for the initiation of desire. Buying the wrong one of the 2 is the single commonest disappointment in this goal.
2. Melanocortin tone in the hypothalamus. Alpha-MSH acting at MC3 and MC4 receptors, particularly in the paraventricular nucleus, is a pro-sexual signal that sits upstream of the dopaminergic pathway rather than beside it. Bremelanotide is a cyclic analog of that peptide, and in two randomized phase 3 trials it produced statistically significant increases in sexual desire scores (0.30 and 0.42, both P<.001) against placebo Kingsberg 2019. Small numbers on a scale, reproduced in 2 randomized trials, in a condition where nothing else worked.
3. Dopaminergic incentive salience, and its inverse, which is a single hormone. Mesolimbic dopamine encodes wanting rather than liking through D1 and D2 receptors, which is why the pathway is the right target for a desire complaint and the wrong one for an anhedonia complaint. Prolactin is the counterweight: it rises after orgasm and is part of the refractory period, and tonically raised prolactin suppresses GnRH pulsatility and desire together.
4. Whether something is holding the system down, which for 59.1% of one cohort was a prescription. Serotonergic antidepressants produced sexual dysfunction in 59.1% of 1,022 outpatients with wide variation between agents Montejo 2001. A melanocortin agonist added on top of a receptor-level suppressant is a second variable rather than a solution.
5. Hormonal substrate, which sets a floor near 300 ng/dL and not a ceiling. Testosterone sets a threshold under desire in both sexes, and above that threshold more of it does not produce more wanting. Hormonal substrate — testosterone, estrogen, prolactin, thyroid is where that argument belongs.

The order to run these in, and what has to be true first

Measure the two hormones that are commonly the whole answer, remove what is suppressing the system, then work centrally. The peptides are third because 2 of the things above them are free.

1. Prolactin and TSH (Thyroid-Stimulating Hormone) first, because both are one draw and both are frequently the explanation. A raised prolactin has a structured differential that runs from drugs to a pituitary adenoma, and the international consensus sets out how it is worked up Petersenn 2023. Macroprolactin, a biologically inactive immunoglobulin-bound complex, accounts for a meaningful share of raised results and is excluded by a specific request to the laboratory rather than by repeating the same assay Sharma 2021.
2. Then Total Testosterone with Free Testosterone, SHBG (Sex Hormone-Binding Globulin) and Estradiol, Sensitive (LC/MS-MS). These are floor checks. In men the sensitive estradiol assay matters because immunoassays are unreliable at male concentrations, and estradiol is itself a determinant of male desire, which surprises people who have spent a year suppressing it.
3. Cabergoline only against a raised prolactin, and its receptor effect outlasts its plasma half-life. It is a long-acting D2 agonist with a plasma half-life measured in days and a pituitary effect that outlasts it, which is why weekly dosing works. With a normal prolactin it has no substrate to act on, and the ergot class carries valvular concerns at the far higher doses used in Parkinson disease.
4. PT-141 is the item on this pathway with 2 phase 3 trials behind it. It is bremelanotide, given on demand rather than daily, and its dose-limiting effect is nausea; a transient rise in blood pressure with a fall in heart rate is a known pharmacodynamic effect of the class. The trials were run in premenopausal women Kingsberg 2019.
5. Melanotan 2 is the non-selective ancestor of that molecule, active at 3 receptor subtypes instead of 2. It is an alpha-MSH analog with activity at MC1R as well as MC3R and MC4R, which is where the tanning comes from and is also the reason for the darkening of existing nevi that is reported with it. The selectivity argument is the whole reason a clinical program spent years producing a different peptide.
6. Apomorphine, Oxytocin and Kisspeptin are three different central mechanisms with three different delivery problems. Apomorphine is a D1 and D2 agonist whose emetic effect is mediated at the area postrema, which is outside the blood-brain barrier. Oxytocin is a nonapeptide with a plasma half-life of minutes. Kisspeptin acts on the GnRH neuron through the KISS1R receptor and has been studied for its effects on sexual brain processing rather than on hormones alone.
7. Mucuna Pruriens, Maca, Damiana and Horny Goat Weed are the botanical tail, and one of them is on the wrong page. Mucuna supplies L-DOPA, most of which is decarboxylated peripherally without a peripheral decarboxylase inhibitor. Icariin, the active in horny goat weed, is a weak PDE5 inhibitor, which makes it a vascular agent sitting on a central pathway and belongs to Vascular & erectile function.

What gets bought for this that cannot move it

A vasodilator cannot create desire, and the cGMP mechanism explains why cleanly. PDE5 inhibition prevents the breakdown of cyclic GMP in corpus cavernosum smooth muscle, which amplifies a nitric oxide signal that only exists once arousal has already been initiated. No arousal, no cGMP, and nothing for the 4 to 17 hours of drug exposure to preserve. The registration data is about successful attempts in men with erectile dysfunction Goldstein 1998, which is a different end point from wanting to make an attempt.

The category that fails structurally on this page is anything peripheral sold as central. Nitric oxide precursors, flavanols and PDE5-adjacent botanicals all act on the endothelium and vascular smooth muscle. They are reasonable products with a mechanism, and the mechanism is in the wrong organ for this complaint.

Melanotan-2 is the item whose downside is not reversible, because MC1R sits on the melanocyte. MC1R agonism increases eumelanin synthesis in melanocytes, and darkening or change in existing moles is reported with it. That is a signal worth taking seriously in its own right, and it is the reason the selective MC4R-directed compound exists rather than a convenience.

And if a drug is producing the effect, this page cannot outrun it. Six or seven readers in ten on some serotonergic agents will have sexual dysfunction attributable to the drug Montejo 2001, and the conversation that changes that is with the prescriber. Stress, sleep and the things that quietly kill desire is the page for the conditions half, and Hormonal substrate — testosterone, estrogen, prolactin, thyroid for the substrate half. Both are cheaper than anything here, and both start with 1 blood draw.

How you would know it was working, on a real read-out and a real timescale

The prediction is falsifiable in a way most libido claims are not: a central agent should change desire without changing any hormone, and a hormonal cause should change a hormone before it changes desire. If both move together inside 4 weeks, look for a third thing that changed.

• Prolactin once, drawn without exercise, nipple stimulation or a struggle at the needle beforehand. Prolactin is pulsatile and stress-responsive, so a mildly raised single value is repeated rather than acted on, and macroprolactin is excluded before any imaging is contemplated Sharma 2021 Petersenn 2023.
• Total Testosterone with SHBG (Sex Hormone-Binding Globulin) on a morning draw, twice if the first is low. This is a threshold question rather than an optimization one, and a result above 400 ng/dL usually rules the hormonal explanation out.
• Estradiol, Sensitive (LC/MS-MS) rather than Estradiol, Standard (ECLIA) in men. Only the mass spectrometry method resolves the range that matters at male concentrations, and a suppressed estradiol on an aromatase inhibitor is a common and entirely iatrogenic cause of exactly this complaint.
• TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine) once. Both directions of thyroid dysfunction reduce desire through a nuclear receptor and both are treatable, which makes this the cheapest test on the page with the highest chance of ending the question.
• Desire itself, counted rather than remembered, over 4 weeks. Number of days on which desire was spontaneously present, written down daily, is a harder measure than a retrospective rating and is the only end point the phase 3 trials could use Kingsberg 2019.

What will fool you. An on-demand injectable carries a large anticipation effect, and the placebo arms in this field move substantially. Nausea is common enough with melanocortin agonists to unblind somebody to their own treatment, which inflates the apparent response. And a good month in a relationship moves this end point more than any molecule on the page, which is why 4 weeks of daily counting beats 1 retrospective judgment.

Sources read for these sections

• Kingsberg SA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology 2019;134(5):899-908 · PMID 31599840
• Petersenn S, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nature Reviews Endocrinology 2023 · PMID 37670148
• Sharma LK, et al. Prevalence of Macroprolactinemia in People Detected to Have Hyperprolactinemia. Journal of Laboratory Physicians 2021 · PMID 34975255
• Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.. N Engl J Med 1998 · PMID 9580646
• Montejo AL. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Journal of Clinical Psychiatry 2001;62 Suppl 3:10-21 · PMID 11229449